MedTrace Logo

Esomeprazole And Symptomatic Response In Patients With Or Without An Elevated Risk For Non-Steroidal Anti-Inflammatory Drug (NSAID)-Associated GI Damage

NCT00524329 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1220

Last updated 2008-09-26

No results posted yet for this study

Summary

The purpose of this study is to compare the treatment effect in patients with upper gastro-intestinal complaints with an elevated risk for NSAID-associated GI-damage to those without an elevated risk for NSAID-associated damage (as determined by the treating physician).

Conditions

  • Heartburn

Sponsors & Collaborators

Principal Investigators

  • Andrea Sellink · AstraZeneca

  • N van den Berk · AstraZeneca

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2007-03-31
Completion
2007-10-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00524329 on ClinicalTrials.gov